Disease on EC 3.5.1.98 - histone deacetylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Achondroplasia
HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Acne Vulgaris
Short-Chain Fatty Acids from Cutibacterium acnes Activate Both a Canonical and Epigenetic Inflammatory Response in Human Sebocytes.
ACTH-Secreting Pituitary Adenoma
HDAC2 Expression and Variable Number of Repeats in Exon 1 of the HDAC2 Gene in Corticotroph Adenomas.
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.
Acute Kidney Injury
A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury.
Alpha-2 adrenoceptor agonist-dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5.
Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Class I HDAC activity is required for renal protection and regeneration after acute kidney injury.
HDAC inhibitors in kidney development and disease.
Histone deacetylase inhibitors protect against cisplatin-induced acute kidney injury by activating autophagy in proximal tubular cells.
Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
Selective Histone Deacetylase 6 Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress and Apoptosis.
Suppression of BMP-7 by histone deacetylase 2 promoted apoptosis of renal tubular epithelial cells in acute kidney injury.
The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury.
The Nephroprotective Effect of MS-275 on Lipopolysaccharide (LPS)-Induced Acute Kidney Injury by Inhibiting Reactive Oxygen Species (ROS)-Oxidative Stress and Endoplasmic Reticulum Stress.
Acute Lung Injury
Cigarette Smoke Disrupted Lung Endothelial Barrier Integrity and Increased Susceptibility to Acute Lung Injury via Histone Deacetylase 6.
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice.
Histone Deacetylase Inhibitors Attenuate Acute Lung Injury During Cecal Ligation and Puncture-Induced Polymicrobial Sepsis.
Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function.
Adenocarcinoma
(-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC?1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity.
2,4?Di?tert?butylphenol, a potential HDAC6 inhibitor, induces senescence and mitotic catastrophe in human gastric adenocarcinoma AGS cells.
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors.
Broccoli Sprouts Delay Prostate Cancer Formation and Decrease Prostate Cancer Severity with a Concurrent Decrease in HDAC3 Protein Expression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice.
Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas.
CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A.
Effects of histone deacetylase inhibitors on p55CDC/Cdc20 expression in HT29 cell line.
Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung.
Epigenetic alterations in TRAMP mice: epigenome DNA methylation profiling using MeDIP-seq.
Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.
Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study.
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma.
HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.
HDAC3 overexpression and colon cancer cell proliferation and differentiation.
HDAC6 is required for invadopodia activity and invasion by breast tumor cells.
High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas.
Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1.
Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells.
Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines.
Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.
Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation, in part, via transcriptional repression of histone H3 lysine 4 demethylases.
Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells.
Impact of The Hybrid-Polar Histone Deacetylase Inhibitor M-Carboxycinnamic Acid Bis-Hydroxamide on Human Pancreatic Adenocarcinoma Cells.
In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs.
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.
Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.
Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma.
MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Predicting chemotherapeutic drug combinations through gene network profiling.
RAR? acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.
Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
Retraction Note to: MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.
SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin.
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b.
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2.
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells.
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Adenocarcinoma of Lung
AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.
Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.
HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways.
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma.
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
Histone deacetylase 5 promotes the proliferation and invasion of lung cancer cells.
Long noncoding RNA MALAT1 regulates HDAC4-mediated proliferation and apoptosis via decoying of miR-140-5p in osteosarcoma cells.
Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1.
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells.
Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Up-regulation of IRF-3 expression through GATA-1 acetylation by histone deacetylase inhibitor in lung adenocarcinoma A549 cells.
[Relationship between expression of HDAC2, IL-8, TNF-? in lung adenocarcinoma tissues and smoking].
Adenocarcinoma, Follicular
Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma.
Adenoma
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
HDAC2 Expression and Variable Number of Repeats in Exon 1 of the HDAC2 Gene in Corticotroph Adenomas.
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Influence of miRNA-106b and miRNA-135a on butyrate-regulated expression of p21 and Cyclin D2 in human colon adenoma cells.
Regulation of prostaglandin transporters in colorectal neoplasia.
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Adenomatous Polyposis Coli
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Histone deacetylase expression in white matter oligodendrocytes after stroke.
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Adenomyosis
Elevated Immunoreactivity against Class I Histone Deacetylases in Adenomyosis.
Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent.
Adenoviridae Infections
Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells.
Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells.
The adenovirus-2 E1B-55K protein interacts with a mSin3A/histone deacetylase 1 complex.
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Adrenal Cortex Neoplasms
Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
Adrenal Gland Neoplasms
Management of patients with adrenal cancer: recommendations of an international consensus conference.
Adrenocortical Carcinoma
Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells.
Adrenoleukodystrophy
HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
African Swine Fever
Analysis of HDAC6 and BAG3-aggresome pathways in African swine fever viral factory formation.
Agenesis of Corpus Callosum
De novo satellited 2q associated with corpus callosum dysgenesis, short stature, mental retardation and developmental delay.
Alexander Disease
Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant.
Alopecia
Disrupted Ectodermal Organ Morphogenesis in Mice with a Conditional Histone Deacetylase 1, 2 Deletion in the Epidermis.
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis.
alpha-tubulin n-acetyltransferase deficiency
MEC-17 Deficiency Leads to Reduced ?-Tubulin Acetylation and Impaired Migration of Cortical Neurons.
Alveolar Bone Loss
Histone deacetylase inhibitors and periodontal bone loss.
Alzheimer Disease
(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.
3,4-Dihydroxyphenylethanol Assuages Cognitive Impulsivity in Alzheimer's Disease by Attuning HPA-Axis via Differential Crosstalk of ?7 nAChR with MicroRNA-124 and HDAC6.
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
An epigenetic blockade of cognitive functions in the neurodegenerating brain.
Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression.
Bioinformatics methods in drug repurposing for Alzheimer's disease.
Biophenols: Enzymes (?-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.).
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
c-Abl stabilizes HDAC2 levels by tyrosine phosphorylation repressing neuronal gene expression in Alzheimer's disease.
Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus.
Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease.
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Discovery of in-vivo chemical probes for treating Alzheimer´s disease: Dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitors.
Epigenetic regulation of HDAC1 SUMOylation as an endogenous neuroprotection against A? toxicity in a mouse model of Alzheimer's disease.
HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease.
HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.
HDAC6 regulates mitochondrial transport in hippocampal neurons.
Histone deacetylase 6 interacts with the microtubule-associated protein tau.
Histone Deacetylase Inhibitor Alleviates the Neurodegenerative Phenotypes and Histone Dysregulation in Presenilins-Deficient Mice.
Histone Deacetylases 1 and 2 Regulate Microglia Function during Development, Homeostasis, and Neurodegeneration in a Context-Dependent Manner.
How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.
In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease.
Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of A?-induced impaired axonal transport.
Loss of HDAC5 Impairs Memory Function: Implications for Alzheimer's Disease.
MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric A?25-35 -induced anxiety and cognitive deficits in a mouse model.
Molecular dynamics and quantum chemistry-based approaches to identify isoform selective HDAC2 inhibitor - a novel target to prevent Alzheimer's disease.
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice.
Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.
Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system.
Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.
Re-exploring the core genes and modules in the human frontal cortex during chronological aging: insights from network-based analysis of transcriptomic studies.
Recent studies on cellular and molecular mechanisms in Alzheimer's disease: focus on epigenetic factors and histone deacetylase.
Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease.
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression.
Targeting Class I Histone Deacetylases in a "Complex" Environment.
Targeting HDACs: a promising therapy for Alzheimer's disease.
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
The role of ATM and DNA damage in neurons: upstream and downstream connections.
The Role of HDAC6 in Alzheimer's Disease.
The Transcription Factor Sp3 Cooperates with HDAC2 to Regulate Synaptic Function and Plasticity in Neurons.
Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
[Epigenetics and etiology of neurodegenerative diseases].
Amyloidosis
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Amyotrophic Lateral Sclerosis
Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.
Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis.
HDAC6 is a Bruchpilot deacetylase that facilitates neurotransmitter release.
HDAC6 maintains mitochondrial connectivity under hypoxic stress by suppressing MARCH5/MITOL dependent MFN2 degradation.
Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis.
Histone deacetylase 6 delays motor neuron degeneration by ameliorating the autophagic flux defect in a transgenic mouse model of amyotrophic lateral sclerosis.
Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression.
Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes.
Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity.
Anaphylaxis
DNA methyl transferase I acts as a negative regulator of allergic skin inflammation.
Histone Deacetylase 3 Mediates Allergic Skin Inflammation by Regulating Expression of MCP1 Protein.
Histone deacetylase-3mediates positive feedback relationship between anaphylaxis and tumor metastasis.
Anemia
Assessing new therapies and their overall impact in myelofibrosis.
Role of stem cell factor in the reactivation of human fetal hemoglobin.
Anemia, Hemolytic
Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.
Anemia, Refractory
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Anemia, Refractory, with Excess of Blasts
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Anemia, Sickle Cell
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.
Mechanisms of human gamma-globin transcriptional induction by apicidin involves p38 signaling to chromatin.
Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Role of stem cell factor in the reactivation of human fetal hemoglobin.
Anthrax
HDAC8 Prevents Anthrax Lethal Toxin-induced Cell Cycle Arrest through Silencing PTEN in Human Monocytic THP-1 Cells.
Inhibition of IL-1? Expression by Anthrax Lethal Toxin is Reversed by HDAC8 Inhibition in Murine Macrophages.
Inhibition of interleukin 1? (IL-1?) expression by anthrax lethal toxin (LeTx) is reversed by histone deacetylase 8 (HDAC8) inhibition in murine macrophages.
Aortic Aneurysm, Abdominal
A Novel Histone Deacetylase Inhibitor Reduces Abdominal Aortic Aneurysm Formation in Angiotensin II-Infused Apolipoprotein E-Deficient Mice.
Aortic Valve Stenosis
Histone deacetylase 6 reduction promotes aortic valve calcification via an endoplasmic reticulum stress-mediated osteogenic pathway.
Arrhythmias, Cardiac
Changes in cardiac NaV1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.
Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice.
Arteriosclerosis
Epigenetics in Vascular Disease - Therapeutic Potential of New Agents.
Arthritis
A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model.
Epigenetics of inflammatory arthritis.
Genome-wide expression and methylation profiling reveal candidate genes in osteoarthritis.
HDACi and Nrf2: not from alpha to omega but from acetylation to OA.
Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice.
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.
Histone deacetylases in RA: epigenetics and epiphenomena.
Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis.
Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.
Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.
Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.
Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo.
Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model.
Arthritis, Experimental
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.
Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.
Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis.
Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes.
Arthritis, Juvenile
Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.
Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.
Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.
Arthritis, Rheumatoid
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.
AAA-ATPase p97 suppresses apoptotic and autophagy-associated cell death in rheumatoid arthritis synovial fibroblasts.
Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation.
HDAC Inhibition in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.
Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis.
Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-{kappa}B p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells.
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.
Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients.
Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis.
Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression.
Largazole, a class I histone deacetylase inhibitor, enhances TNF-?-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts.
Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009.
Reduced Activity of HDAC3 and Increased Acetylation of Histones H3 in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis.
Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.
Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.
The histone deacetylase inhibitors MS-275 and SAHA suppress the p38 mitogen-activated protein kinase signaling pathway and chemotaxis in rheumatoid arthritic synovial fibroblastic E11 cells.
Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes.
Trichostatin A cooperates with fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts.
Trichostatin A, an Inhibitor of Histone Deacetylase, Inhibits the Viability and Invasiveness of Hypoxic Rheumatoid Arthritis Fibroblast-Like Synoviocytes via PI3K/Akt Signaling.
Aspergillosis
Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis.
Asthma
Activation of AMPK inhibits TGF-?1-induced airway smooth muscle cells proliferation and its potential mechanisms.
Asthma in smokers: challenges and opportunities.
Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch.
Corticosteroid insensitivity in smokers with asthma : clinical evidence, mechanisms, and management.
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.
Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review.
Effects of Macrolide and Corticosteroid in Neutrophilic Asthma Mouse Model.
Epigenetic regulation of airway inflammation.
Epigenetics and chromatin remodeling play a role in lung disease.
Epigenetics in asthma and other inflammatory lung diseases.
Expression and activity of histone deacetylases in human asthmatic airways.
Glucocorticoid receptor ? and histone deacetylase 1 and 2 expression in the airways of severe asthma.
Histone acetylation and deacetylation: importance in inflammatory lung diseases.
Histone deacetylase 6 (HDAC6) is an essential factor for oocyte maturation and asymmetric division in mice.
Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma.
Histone deacetylase inhibitor regulates the balance of Th17/Treg in allergic asthma.
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
Histone deacetylase inhibitors: can we consider potent anti-neoplastic agents for the treatment of asthma?
Histone deacetylase-2 and airway disease.
Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions.
Histone deacetylation: an important mechanism in inflammatory lung diseases.
How corticosteroids control inflammation: Quintiles Prize Lecture 2005.
Identification of differentially expressed genes associated with asthma in children based on the bioanalysis of the regulatory network.
Increased glucocorticoid receptor-beta expression, but not decreased histone deacetylase 2, in severe asthma.
Inflammation 2005 - Seventh World Congress. Respiratory inflammation.
Inhibition of histone deacetylase 2 expression by elevated glucocorticoid receptor beta in steroid-resistant asthma.
Low-level laser therapy suppresses the oxidative stress-induced glucocorticoids resistance in U937 cells: relevance to cytokine secretion and histone deacetylase in alveolar macrophages.
MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2.
Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages.
Pathogenesis of severe asthma.
Potential non-oncological applications of histone deacetylase inhibitors.
Protective effects of valproic acid against airway hyperresponsiveness and airway remodeling in a mouse model of allergic airways disease.
Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma.
Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma.
Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma.
Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease.
The influence of smoking on the treatment response in patients with asthma.
The role of HDAC2 in cigarette smoke-induced airway inflammation in a murine model of asthma and the effect of intervention with roxithromycin.
The role of histone deacetylases in asthma and allergic diseases.
Theophylline.
Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo.
Therapeutic effects of histone deacetylase inhibitors in a murine asthma model.
Treating patients with respiratory disease who smoke.
Treatment with 1,25(OH)2D3 induced HDAC2 expression and reduced NF-?B p65 expression in a rat model of OVA-induced asthma.
Trichostatin A Abrogates Airway Constriction, but not Inflammation in Mouse and Human Asthma Models.
Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models.
USP17-mediated deubiquitination and stabilization of HDAC2 in cigarette smoke extract-induced inflammation.
[Characteristics of histone deacetylase 9 in peripheral blood of patients with bronchial asthma].
[Roles of histone acetyltransferase and histone deacetylase in the pathogenesis of bronchial asthma].
[Therapeutic effects of histone deacetylase inhibitor givinostat on air inflammation and high airway resistance in a murine asthma model].
[Therapeutic effects of Tubastatin A Hcl on airway inflammation in acute mice asthma model].
Astrocytoma
Abnormal methylation of histone deacetylase genes: implications on etiology and epigenetic therapy of astrocytomas.
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.
Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours.
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas.
HDAC6 mediates HIV-1 tat-induced proinflammatory responses by regulating MAPK-NF-kappaB/AP-1 pathways in astrocytes.
The role of DNA methylation and histone acetylation in the regulation of progesterone receptor isoforms expression in human astrocytoma cell lines.
Ataxia
The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.
Ataxia Telangiectasia
ATM modulates transcription in response to histone deacetylase inhibition as part of its DNA damage response.
Modulation of chromatin conformation by the histone deacetylase inhibitor trichostatin A promotes the removal of radiation-induced lesions in ataxia telangiectasia cell lines.
Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia.
Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated.
Role of chromatin structure modulation by the histone deacetylase inhibitor trichostatin A on the radio-sensitivity of ataxia telangiectasia.
Atherosclerosis
ApoE-/- PGC-1?-/- Mice Display Reduced IL-18 Levels and Do Not Develop Enhanced Atherosclerosis.
Estrogen modulates vascular smooth muscle cell function through downregulation of SIRT1.
Fluid shear stress stimulates phosphorylation-dependent nuclear export of HDAC5 and mediates expression of KLF2 and eNOS.
Histone deacetylase 3 is critical in endothelial survival and atherosclerosis development in response to disturbed flow.
Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development.
Inhibiting epigenetic enzymes to improve atherogenic macrophage functions.
Inhibition of miR?34a prevents endothelial cell apoptosis by directly targeting HDAC1 in the setting of atherosclerosis.
Involvement of the Antioxidant Effect and Anti-inflammatory Response in Butyrate-Inhibited Vascular Smooth Muscle Cell Proliferation.
miR-34a Targets HDAC1-Regulated H3K9 Acetylation on Lipid Accumulation Induced by Homocysteine in Foam Cells.
New role for histone deacetylase 9 in atherosclerosis and inflammation.
Protein kinase B mediates insulin-like growth factor 1-induced phosphorylation and nuclear export of histone deacetylase 5 via NADPH oxidase 4 activation in vascular smooth muscle cells.
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.
The involvement of NFAT transcriptional activity suppression in SIRT1-mediated inhibition of COX-2 expression induced by PMA/Ionomycin.
Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice.
Atrial Fibrillation
Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.
Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy.
Atrioventricular Block
Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog.
Atypical Squamous Cells of the Cervix
MoSnt2-dependent deacetylation of histone H3 mediates MoTor-dependent autophagy and plant infection by the rice blast fungus Magnaporthe oryzae.
Autoimmune Diseases
Association between functional SIRT1 polymorphisms and the clinical characteristics of patients with autoimmune thyroid disease.
CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus.
Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Effects of trichostatin A in a rat model of acute graft-versus-host disease after liver transplantation.
Epigenetic Alterations and MicroRNA Misexpression in Cancer and Autoimmune Diseases: a Critical Review.
Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.
Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
Histone Deacetylase 7 mediates tissue-specific autoimmunity via control of innate effector function in invariant Natural Killer T Cells.
Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms.
Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis.
The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells.
Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells.
Trichostatin Differentially Regulates Th1 and Th2 Responses and Alleviates Rheumatoid Arthritis in Mice.
Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells.
Autoimmune Lymphoproliferative Syndrome
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).
Bacterial Infections
Augmentation of Cationic Antimicrobial Peptide Production with Histone Deacetylase Inhibitors as a Novel Epigenetic Therapy for Bacterial Infections.
HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes.
beta-Thalassemia
Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia.
Mechanisms of human gamma-globin transcriptional induction by apicidin involves p38 signaling to chromatin.
Biliary Tract Neoplasms
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis.
Blast Crisis
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
The Long Noncoding RNA MEG3 and its Target miR-147 Regulate JAK/STAT Pathway in Advanced Chronic Myeloid Leukemia.
Blindness
HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
Bloom Syndrome
Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor.
Bone Diseases
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Bone Diseases, Metabolic
Hdac3 Deficiency Increases Marrow Adiposity and Induces Lipid Storage and Glucocorticoid Metabolism in Osteochondroprogenitor Cells.
Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion.
Sirt6 cooperates with Blimp1 to positively regulate osteoclast differentiation.
Bone Neoplasms
HDAC inhibitor TSA ameliorates mechanical hypersensitivity and potentiates analgesic effect of morphine in a rat model of bone cancer pain by restoring ?-opioid receptor in spinal cord.
Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain.
Bone Resorption
Compounds that inhibit histone deacetylases in class I and class II effectively suppress human osteoclasts in vitro.
Deletion of histone deacetylase 7 in osteoclasts decreases bone mass in mice by interactions with MITF.
HDAC2 Regulates FOXO1 during RANKL-Induced Osteoclastogenesis.
HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered ?-catenin switch.
Histone deacetylase 3 is required for maintenance of bone mass during aging.
SIKs control osteocyte responses to parathyroid hormone.
The Role of FoxOs in Bone Health and Disease.
Brachydactyly
Dose dependent expression of HDAC4 causes variable expressivity in a novel inherited case of brachydactyly mental retardation syndrome.
Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.
Haploinsufficiency of HDAC4 does not cause intellectual disability in all affected individuals.
Phenotypic variant of Brachydactyly-mental retardation syndrome in a family with an inherited interstitial 2q37.3 microdeletion including HDAC4.
Primary hyperoxaluria type 1 and brachydactyly mental retardation syndrome caused by a novel mutation in AGXT and a terminal deletion of chromosome 2.
The first familial case of inherited 2q37.3 interstitial deletion with isolated skeletal abnormalities including brachydactyly type E and short stature.
Transcriptome analysis of genes and gene networks involved in aggressive behavior in mouse and zebrafish.
[Analysis of clinical phenotypes and genetic variations in a Chinese family affected with craniofacial and skeletal deformities].
Bradycardia
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
Brain Concussion
Repeated mild traumatic brain injury causes persistent changes in histone deacetylase function in hippocampus: Implications in learning and memory deficits in rats.
Brain Diseases
A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests.
Aberrant Expression of Histone Deacetylases 4 in Cognitive Disorders: Molecular Mechanisms and a Potential Target.
Class I Histone Deacetylase Inhibitor Valproic Acid Reverses Cognitive Deficits in a Mouse Model of Septic Encephalopathy.
HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway.
Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.
Salvianolic acid B attenuates apoptosis and inflammation via SIRT1 activation in experimental stroke rats.
Targeting the correct HDAC(s) to treat cognitive disorders.
Brain Edema
Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock.
[Protective effect of the histone deacetylase inhibitor ACY1215 against brain edema in mice with acute liver failure].
Brain Infarction
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of ?-tubulin acetylation and FGF-21 up-regulation.
Brain Injuries
Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies.
Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.
Magnolol attenuates the inflammation and apoptosis through the activation of SIRT1 in experimental stroke rats.
Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury.
SIRT1 attenuated oxidative stress induced by methyl tert-butyl ether in HT22 cells.
The potential neuroprotective role of a histone deacetylase inhibitor, sodium butyrate, after neonatal hypoxia-ischemia.
Uridine protects against hypoxic-ischemic brain injury by reducing histone deacetylase activity in neonatal rats.
Brain Injuries, Traumatic
Development of a novel neuroprotective strategy: combined treatment with hypothermia and valproic acid improves survival in hypoxic hippocampal cells.
Effect of pharmacologic resuscitation on the brain gene expression profiles in a swine model of traumatic brain injury and hemorrhage.
HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway.
Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury.
Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury.
Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock.
Scriptaid, a novel histone deacetylase inhibitor, protects against traumatic brain injury via modulation of PTEN and AKT pathway : scriptaid protects against TBI via AKT.
Treatment with a histone deacetylase inhibitor, valproic acid, is associated with increased platelet activation in a large animal model of traumatic brain injury and hemorrhagic shock.
Brain Ischemia
Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke.
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.
Molecular switching from ubiquitin-proteasome to autophagy pathways in mice stroke model.
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Neuroprotective effects of histone deacetylase inhibitors in brain ischemia.
Protective effects of ex-527 on cerebral ischemia-reperfusion injury through necroptosis signaling pathway attenuation.
Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window.
The Emerging Role of Epigenetics in Cerebral Ischemia.
The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain.
The role of histone deacetylase inhibitors in regulation of Akt/GSK-3? signaling pathway in mice following transient focal cerebral ischemia.
Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition.
Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction.
Brain Neoplasms
A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.
Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation.
Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells.
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis resistant mammary and brain cancer stem cells thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Identification of a Drosophila Myb-E2F2/RBF transcriptional repressor complex.
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells.
NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells.
Novel histone deacetylase inhibitors for the treatment of pediatric brain tumors.
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition.
Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence.
The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.
Breast Neoplasms
4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.
?-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells.
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382.
A genomic approach to predict synergistic combinations for breast cancer treatment.
A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells.
A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth.
A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
A role for paralog-specific sumoylation in histone deacetylase 1 stability.
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.
Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer.
An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.
An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex.
Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.
Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
Aromatase inhibitors and xenograft studies.
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells.
ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion.
Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells.
Bioimpedance rise in response to histone deacetylase inhibitor is a marker of mammary cancer cells within a mixed culture of normal breast cells.
Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.
Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ER? coinhibition.
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer.
Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.
Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex.
Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene.
CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Chemopreventive and chemotherapeutic effect of a novel histone deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human breast cancer cells.
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.
Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
Correction: HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells.
Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.
DBC1/CCAR2 and CCAR1 Are Largely Disordered Proteins that Have Evolved from One Common Ancestor.
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.
Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Defining the Role of Histone Deacetylases in the Inhibition of Mammary Carcinogenesis by Dietary Energy Restriction (DER): Effects of Suberoylanilide Hydroxamic Acid (SAHA) and DER in a Rat Model.
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.
Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1? synthesis, and decreases breast cancer metastasis.
Dietary polyphenols may affect DNA methylation.
Differential distribution of unmodified and phosphorylated histone deacetylase 2 in chromatin.
Differential Regulation of Estrogen Receptor ? Expression in Breast Cancer Cells by Metastasis-Associated Protein 1.
Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells.
Downregulation of Hypoxia-related Responses by Novel Antitumor Histone Deacetylase Inhibitors in MDAMB231 Breast Cancer Cells.
Downregulation of the Ca(2+)-activated K(+) channel KC a3.1 by histone deacetylase inhibition in human breast cancer cells.
Downregulation of TXNIP leads to high proliferative activity and estrogen-dependent cell growth in breast cancer.
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Effect of suberoylanilide hydroxamic acid (SAHA) on breast cancer cells within a tumor-stroma microfluidic model.
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
EFFECTS OF THE PESTICIDE CHLORPYRIFOS ON BREAST CANCER DISEASE. IMPLICATION OF EPIGENETIC MECHANISMS.
Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.
Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells.
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Epigenetic control of group V phospholipase A2 expression in human malignant cells.
Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.
Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy.
Epigenetic regulation of soluble guanylate cyclase (sGC) ?1 in breast cancer cells.
Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells.
Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells.
Epigenetic silencing of the tumor suppressor klotho in human breast cancer.
Epigenetic targeting in breast cancer: therapeutic impact and future direction.
Epigenetic Therapy in Breast Cancer.
ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells.
Estrogen signaling in cancer microenvironment and prediction of response to hormonal therapy.
Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.
Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.
Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis.
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
Function of Histone deacetylase 6 as a cofactor of nuclear receptor coregulator LCoR.
Functional activation of the estrogen receptor-? and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis.
Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL.
HDAC Inhibitors Target HDAC5, Upregulate MicroRNA-125a-5p, and Induce Apoptosis in Breast Cancer Cells.
HDAC1 Expression in Invasive Ductal Carcinoma of the Breast and Its Value as a Good Prognostic Factor.
HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8.
HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.
HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.
HDAC3 regulates stability of estrogen receptor ? mRNA.
HDAC3 selectively represses CREB3-mediated transcription and migration of metastatic breast cancer cells.
HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.
HDAC6 deacetylates survivin for its nuclear export in breast cancer.
HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells.
HDAC6 expression is correlated with better survival in breast cancer.
HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation.
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
HDAC6 is required for invadopodia activity and invasion by breast tumor cells.
High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients.
Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Histone deacetylase 3 is negatively regulated by the nuclear protein deleted in breast cancer 1 (DBC1).
Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells.
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway.
Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals.
Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.
Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU.
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer.
Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells.
Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca(2+) Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Histone deacetylase inhibitor- and PMA-induced upregulation of PMCA4b enhances Ca2+ clearance from MCF-7 breast cancer cells.
Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.
Histone Deacetylase Inhibitors Enhance Cytotoxicity Towards Breast Tumors While Preserving the Wound-Healing Function of Adipose-Derived Stem Cells.
Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines.
Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.
Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines.
Histone deacetylase inhibitors sensitize 5-fluorouracil-resistant MDA-MB-468 breast cancer cells to 5-fluorouracil.
Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells through WNT/?-catenin Signaling.
Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Histone deacetylase inhibitors: the Abbott experience.
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.
Histone Deacetylase-3 Modification of MicroRNA-31 Promotes Cell Proliferation and Aerobic Glycolysis in Breast Cancer and Is Predictive of Poor Prognosis.
Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene.
Hyaluronate synthase-2 overexpression alters estrogen dependence and induces histone deacetylase inhibitor-like effects on ER-driven genes in MCF7 breast tumor cells.
Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line.
Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis.
Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1.
Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells.
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells.
Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Inhibition of proliferation induced by anti-sense RNA of HDAC1 in MCF-7 cells.
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells.
Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer.
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism.
Krüppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion.
Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor.
Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy.
Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer.
Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.
MCF10A and MDA-MB-231 human breast basal epithelial cell co-culture in silicon micro-arrays.
Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer.
Methylomics of breast cancer: Seeking epimarkers in peripheral blood of young subjects.
MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions.
MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.
miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.
miR-200a Regulates SIRT1 Expression and Epithelial to Mesenchymal Transition (EMT)-like Transformation in Mammary Epithelial Cells.
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.
Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells.
Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells.
Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells.
Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions.
Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.
Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.
NEDD9 Regulates Actin Dynamics through Cortactin Deacetylation in an AURKA/HDAC6-dependent Manner.
Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer.
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells.
Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells.
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha.
Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition.
p53 Binds to Estrogen Receptor 1 Promoter in Human Breast Cancer Cells.
PEG-functionalized zinc oxide nanoparticles induce apoptosis in breast cancer cells through reactive oxygen species-dependent impairment of DNA damage repair enzyme NEIL2.
Peroxisome proliferator-activated receptor alpha expression is regulated by estrogen receptor alpha and modulates the response of MCF-7 cells to sodium butyrate.
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.
Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Phthalates Stimulate the Epithelial to Mesenchymal TransitionThrough an HDAC6-Dependent Mechanism in Human BreastEpithelial Stem Cells.
PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.
Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Proteomic Analysis of Epithelial to Mesenchymal Transition (EMT) Reveals Cross-talk between SNAIL and HDAC1 Proteins in Breast Cancer Cells.
Pubertal supplementation of lipotropes in female rats reduces mammary cancer risk by suppressing histone deacetylase 1.
Quantification of SAHA-Dependent Changes in Histone Modifications Using Data-Independent Acquisition Mass Spectrometry.
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1.
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation.
Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin a on the energy metabolism of breast cancer cells.
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug.
Regulation of estrogen receptor ?1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.
Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.
Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer.
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells.
Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines.
Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells.
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
Sp1-mediated TRAIL induction in chemosensitization.
Subcellular Localization of Maspin Correlates with Histone Deacetylase 1 Expression in Human Breast Cancer.
Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
Synergistic epigenetic reactivation of estrogen receptor-? (ER?) by combined green tea polyphenol and histone deacetylase inhibitor in ER?-negative breast cancer cells.
Synthesis and structure-activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy.
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Targeting triple negative breast cancer with histone deacetylase inhibitors.
The actin-binding protein, actinin alpha 4 (ACTN4), is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells.
The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor ? expression.
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells.
The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
The Immunohistochemical Expression and Potential Prognostic Value of HDAC6, AR in Invasive Breast Cancer.
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ER? expression and enhances hormonal therapy for breast cancer.
The promise of using histone deacetylase inhibitors in combination treatment against breast cancer and other solid tumors.
The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells.
The role of HDAC6 in cancer.
The role of histone deacetylase inhibitors in metastatic breast cancer.
The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer.
The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42.
The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2.
The Tumor Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the Beta-catenin Coactivator BCL9-2 in Breast Cancer Cells.
Total synthesis and stereochemical assignment of burkholdac B, a depsipeptide HDAC inhibitor.
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.
Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells.
Trichostatin A enhances acetylation as well as protein stability of ER alpha through induction of p300 protein.
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231.
Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Tyrosine phosphorylation of HDAC3 by Src kinase mediates proliferation of HER2-positive breast cancer cells.
Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer.
Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells.
Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin.
WITHDRAWN: Cross-talk between Wnt and hypoxia signaling pathways in breast cancer cells: Dual role of HDAC1 and beta-catenin.
ZIP restores estrogen receptor expression and response to Tamoxifen in estrogen receptor negative tumors.
[Biological mechanism of full-length form of spleen tyrosine kinase regulating gene transcription in breast cancer cells]
[In vitro study about the inhibitory effect of CDAII in combination with sodium butyrate on breast cancer cells.]
[Sodium valproate enhances doxorubicin cytotoxicity in breast cancer cells in vitro].
Bronchitis
Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma.
Bronchopulmonary Dysplasia
Lipopolysaccharide Induces Up-Regulation of TGF-? through HDAC2 in a Rat Model of Bronchopulmonary Dysplasia.
Burkitt Lymphoma
Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.
Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation.
Histone deacetylase 6 activity is critical for the metastasis of Burkitt's lymphoma cells.
Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.
Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Suberoylanilide hydroxamic acid (SAHA) induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Camurati-Engelmann Syndrome
The new bone biology: pathologic, molecular, and clinical correlates.
Canavan Disease
Acetate supplementation induces growth arrest of NG2/PDGFR?-positive oligodendroglioma-derived tumor-initiating cells.
Candidiasis
Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.
Carcinogenesis
A concern regarding the current confusion with the human homolog of mouse Np95, ICBP90/UHRF1.
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.
A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Autophagic and apoptotic effects of HDAC inhibitors on cancer cells.
Carcinogenic Potential of Biliary Epithelium of Congenital Choledochal Cyst Model in Rats: A Special Reference to HDAC Expression.
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Chromatin remodeling, cancer and chemotherapy.
Cloning, purification, crystallization and preliminary crystallographic analysis of the human histone deacetylase sirtuin 1.
Crosstalk between Wnt Signaling and RNA Processing in Colorectal Cancer.
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans.
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6.
Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis.
Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1alpha to reverse HRE site in the promoter.
Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1.
Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer.
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC(+/min) mouse model.
Epigenetic actions of environmental factors and promising drugs for cancer therapy.
Epigenetic therapy in human choriocarcinoma.
Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
Expression profile of histone deacetylase 1 in gastric cancer tissues.
Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis.
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Functional analysis of a histone deacetylase-like protein of Thermus caldophilus GK24 in mammalian cell.
G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.
Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas.
Genome-wide characterization of lncRNAs in acute myeloid leukemia.
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2.
HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.
HDAC6 and Ovarian Cancer.
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.
HDAC6: Physiological function and its selective inhibitors for cancer treatment.
Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation.
HDAC8: a multifaceted target for therapeutic interventions.
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
Histone deacetylase 1 phosphorylation at S421 and S423 is constitutive in vivo, but dispensable in vitro.
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis.
Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration.
Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1.
Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Histone deacetylase 8 in neuroblastoma tumorigenesis.
Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation.
Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells.
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-? on pancreatic cancer cells.
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: A special reference to gene-expression microarray analysis.
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.
Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro.
Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?
Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer.
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Identification of histone deacetylase 1 protein complexes in liver cancer cells.
Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.
Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis.
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Induction of a novel histone deacetylase 1/c-Myc/Mnt/Max complex formation is implicated in parity-induced refractoriness to mammary carcinogenesis.
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Influence of miRNA-106b and miRNA-135a on butyrate-regulated expression of p21 and Cyclin D2 in human colon adenoma cells.
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Inhibition of proliferation induced by anti-sense RNA of HDAC1 in MCF-7 cells.
Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma.
Mammalian histone deacetylase 1 protein is posttranslationally modified by phosphorylation.
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity.
MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.
miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.
miR-543 promotes gastric cancer cell proliferation by targeting SIRT1.
miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth.
Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges.
Never in mitosis gene A-related kinase 6 and aurora kinase A: New gene biomarkers in the conversion from ulcerative colitis to colorectal cancer.
Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Pin1 Is Involved in HDAC6-mediated Cancer Cell Motility.
Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.
Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy.
Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer.
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.
Psammaplin A is a natural prodrug that inhibits class I histone deacetylase.
PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors.
Regulation of proliferation, apoptosis and cell cycle in gastrointestinal disorders.
Role of SIRT1 in homologous recombination.
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.
Selective inhibition of bicyclic tetrapeptide histone deacetylase inhibitor on HDAC4 and K562 leukemia cell.
Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.
SIRT1 regulates UV-induced DNA repair through deacetylating XPA.
SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer.
SIRT2 Regulates LPS-Induced Renal Tubular CXCL2 and CCL2 Expression.
Sirtuin 1 in immune regulation and autoimmunity.
Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo.
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice.
Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.
Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms.
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma.
The biology of HDAC in cancer: the nuclear and epigenetic components.
The chemopreventive activity of the histone deacetylase inhibitor tributyrin in colon carcinogenesis involves the induction of apoptosis and reduction of DNA damage.
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.
The enzyme activity of histone deacetylase 8 is modulated by a redox-switch.
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
The Proteomic Profile of Deleted in Breast Cancer 1 (DBC1) Interactions Points to a Multifaceted Regulation of Gene Expression.
The role of HDAC6 in cancer.
The therapeutic properties of resminostat for hepatocellular carcinoma.
The Up-Regulation of Histone Deacetylase 8 Promotes Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma.
Time-Dependent Effects of POT1 Knockdown on Proliferation, Tumorigenicity, and HDACi Response of SK-OV3 Ovarian Cancer Cells.
Transcription factors as therapeutic targets in lymphoid malignancies.
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Transforming pathways unleashed by a HDAC2 mutation in human cancer.
Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression.
UHRF1 expression is upregulated and associated with cellular proliferation in colorectal cancer.
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Carcinoid Tumor
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.
Suberoyl bishydroxamic Acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.
Carcinoma
18?-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.
4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
A histone deacetylase inhibitor, trichostatin a, enhances radiosensitivity by abrogating g2/m arrest in human carcinoma cells.
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Activation of PAR4 Upregulates p16 through Inhibition of DNMT1 and HDAC2 Expression via MAPK Signals in Esophageal Squamous Cell Carcinoma Cells.
Activation of the gamma-glutamyltransferase promoter 2 in the rat colon carcinoma cell line CC531 by histone deacetylase inhibitors is mediated through the Sp1 binding motif.
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells.
Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma.
Apoptosis of U937 human leukemic cells by sodium butyrate is associated with inhibition of telomerase activity.
Augmentation of Sodium Butyrate-induced Apoptosis by Phosphatidylinositol 3-kinase Inhibition in the Human Cervical Cancer Cell-line.
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells.
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.
BORIS in human cancers - A review.
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation?
Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids.
Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter.
Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.
Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma.
Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer.
Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy.
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Combination Treatment of Renal Cell Carcinoma with Belinostat and 5-Fluorouracil: A Role for Oxidative Stress Induced DNA Damage and HSP90 Regulated Thymidine Synthase.
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Combined therapy of colon carcinomas with an oncolytic adenovirus and valproic acid.
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Combining Histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.
Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma.
Conjugate of Pt (IV)-Histone Deacetylase Inhibitor as Prodrug for Cancer Chemotherapy.
Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.
Correction to: Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Differential protein acetylation induced by novel histone deacetylase inhibitors.
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor.
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: recruiting histone deacetylase and inhibiting activator protein 1 transcription factors.
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Effect of histone deacetylase on prostate carcinoma.
Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.
Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines.
Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Effects of Down-regulation of HDAC6 Expression on Proliferation, Cell Cycling and Migration of Esophageal Squamous Cell Carcinoma Cells and Related Molecular Mechanisms.
Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines.
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
Effects of trichostatin A on HIF-1? and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Epigenetic control of HNF-4? in colon carcinoma cells affects MUC4 expression and malignancy.
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.
Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.
Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma.
Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation.
Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma.
Functional variants of the NEIL1 and NEIL2 genes and risk and progression of squamous cell carcinoma of the oral cavity and oropharynx.
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression.
Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression.
HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9.
HDAC Inhibitors Synergize Antiproliferative Effect of Sorafenib in Renal Cell Carcinoma Cells.
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.
HDAC10 as a potential therapeutic target in ovarian cancer.
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers.
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
HDAC6 siRNA inhibits proliferation and induces apoptosis of HeLa cells and its related molecular mechanism.
HDACs and HDAC inhibitors in urothelial carcinoma - perspectives for an antineoplastic treatment.
Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer.
Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression.
Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line.
Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of ?-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5?2 signaling pathway.
Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma.
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Histone deacetylase in chronic lymphocytic leukemia.
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma.
Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.
Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Histone deacetylase inhibitor for NUT midline carcinoma.
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.
Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor.
Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression.
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells.
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.
Histone deacetylase inhibitors in oral squamous cell carcinoma treatment.
Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
Histone Deacetylase Inhibitors Modulate Renal Cell Carcinoma Sensitivity to TRAIL/Apo-2L-induced Apoptosis by Enhancing TRAIL-R2 Expression.
Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells.
Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site.
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Histone deacetylase inhibitors synergizes with catalytic inhibitors of EZH2 to exhibit anti-tumor activity in small cell carcinoma of the ovary, hypercalcemic type.
Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo.
Histone deacetylase inhibitors: the Abbott experience.
Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.
Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.
Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays.
Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells.
Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC).
Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon.
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression.
Interaction among Rb/p16, Rb/E2F1 and HDAC1 proteins in gallbladder carcinoma.
Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues.
L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation.
Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.
LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition.
Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells.
Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells.
MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.
MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
MiR-601 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma (ESCC) by targeting HDAC6.
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Modulation of growth and differentiation of human colon carcinoma cells by histone deacetylase inhibitory trichostatins.
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.
New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas.
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1.
Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma.
Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number.
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
Plant polyphenols and oxidative metabolites of the herbal alkenylbenzene methyleugenol suppress histone deacetylase activity in human colon carcinoma cells.
Positive and negative regulation of podoplanin expression by TGF-? and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines.
Potential Anticancer Properties and Mechanisms of Action of Curcumin.
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma.
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
Quantitative phosphoproteomic analysis reveals ?-bisabolene inducing p53-mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1/2 activation.
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
Rapid detection of apoptosis through real-time reverse transcriptase polymerase chain reaction measurement of the small cytoplasmic RNA Y1.
Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.
Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300.
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor.
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: Enhanced DNA damage response.
Sensitization to UV-induced apoptosis by the histone deacetylase inhibitor trichostatin A (TSA).
Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.
Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.
Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3.
SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5.
Suberoylanilide hydroxamic acid (SAHA) induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Sumoylation of HDAC2 promotes NF-?B-dependent gene expression.
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.
The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma.
The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis.
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells.
The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL.
THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID ALTERS GROWTH PROPERTIES OF RENAL CELL CARCINOMA IN VITRO AND IN VIVO.
The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.
Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines.
Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma.
Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines.
Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma.
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
[Down-regulation of histone deacetylase 2 induces cell apoptosis and inhibits cell proliferation and migration of laryngeal squamous cell carcinoma cells].
[Effect of down-regulation of histone deacetylase 2 protein expression on cell proliferation and cell cycle in cervical carcinoma].
[Effect of HDAC6 down-regulation on the growth of xenografted human laryngeal carcinoma cell line Hep-2 in nude mice and underlying mechanism].
[Effects of downregulation of HDAC6 expression on cell cycle, proliferation and migration of laryngeal squamous cell carcinoma].
[Enhancive effect of histone deacetylase inhibitor trichostatin a on transfection efficiency of adenovirus in ovarian carcinoma cell line A2780]
[Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL].
[Role of histone deacetylase in inhibiting invasion of human gastric carcinoma cell line SGC-7901 by PPARgamma-mediated pathway.]
Carcinoma, Basal Cell
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Carcinoma, Ductal
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
HDAC1 Expression in Invasive Ductal Carcinoma of the Breast and Its Value as a Good Prognostic Factor.
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.
The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas.
Carcinoma, Embryonal
A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells.
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
Molecular profiling of embryonal carcinoma cells following retinoic acid or histone deacetylase inhibitor treatment.
Carcinoma, Hepatocellular
1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1).
A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system.
Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins.
Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid.
Andrographolide reduced VEGFA expression in hepatoma cancer cells by inactivating HIF-1?: The involvement of JNK and MTA1/HDCA.
Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2.
Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo.
Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.
AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.
Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model.
C/EBP? negatively regulates SIRT7 expression via recruiting HDAC3 to the upstream-promoter of hepatocellular carcinoma cells.
CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
cDNA microarray analysis in hepatocyte differentiation in Huh 7 cells.
Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.
Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.
Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy.
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.
Correction: Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review.
Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth.
Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics.
Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma.
Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients.
Downregulation of matrix metalloproteinases contributes to the inhibition of cell migration and invasion in HepG2 cells by sodium valproate.
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP.
Effects of cell density and trichostatin A on the expression of HDAC1 and p57Kip2 in Hep 3B cells.
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.
Enrichment of Nur77 mediated by retinoic acid receptor ? leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors.
Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.
Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells.
Growth attenuation is associated with histone deacetylase 10-induced autophagy in the liver.
HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.
HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKT.
Hdac3 is essential for the maintenance of chromatin structure and genome stability.
HDAC5 promotes cell proliferation in human hepatocellular carcinoma by up-regulating Six1 expression.
HDAC6 functions as a tumor suppressor by activating JNK-mediated beclin 1-dependent autophagic cell death in liver cancer.
HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity.
Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells.
Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
Highly expressed histone deacetylase 5 promotes the growth of hepatocellular carcinoma cells by inhibiting the TAp63-maspin pathway.
Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition.
Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.
Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.
Histone deacetylase 5 promotes the migration and invasion of hepatocellular carcinoma via increasing the transcription of hypoxia-inducible factor-1? under hypoxia condition.
Histone Deacetylase HDAC8 Promotes Insulin Resistance and ?-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
Histone deacetylase inhibitor for the treatment of hepatocellular carcinoma: Chemoimmunotherapeutic perspective and prospects.
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells.
Histone deacetylase inhibitors for treatment of hepatocellular carcinoma.
Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.
Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells.
Hypoacetylation in association with histone 3 modulation in human hepatocellular carcinoma.
Identification of a TGF-?-miR-195 positive feedback loop in hepatocytes and its deregulation in hepatoma cells.
Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells.
Identification of histone deacetylase 1 protein complexes in liver cancer cells.
Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.
IGF-II and IL-2 act synergistically to alter HDAC1 expression following treatments with trichostatin a.
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Inhibition of autophagy signi?cantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Inhibitory effects of 1,25(OH)2D3 on the proliferation of hepatocellular carcinoma cells through the downregulation of HDAC2.
Involvement of Insulin-like Growth Factor-binding Protein-3 in the Effects of Histone Deacetylase Inhibitor MS-275 in Hepatoma Cells.
Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation: implications for MAT1A silencing during transformation.
microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells.
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma.
miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4.
Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.
Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[(18)F]-fluorothymidine PET.
mRNA levels of related Abcb genes change opposite to each other upon histone deacetylase inhibition in drug-resistant rat hepatoma cells.
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase II? degradation in hepatocellular carcinoma cells.
Nuclear distribution of histone deacetylase: a marker enzyme for the internal nuclear matrix.
Oncogenic potential of CK2? and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.
Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt/?-catenin signaling pathway in hepatocellular carcinoma.
Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.
Overexpression of Histone Deacetylase and Amyloid Precursor Protein in Hepatocellular Carcinoma.
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
PML suppresses IL-6-induced STAT3 activation by interfering with STAT3 and HDAC3 interaction.
Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma.
Radiosensitizing Effect of a Phenylbutyrate-derived Histone Deacetylase Inhibitor in Hepatocellular Carcinoma.
Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.
Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.
SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Suppressive Effect of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), on Hepatitis C Virus Replication via Epigenetic Changes in Host Cells.
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.
The histone deacetylase 4/Sp1/miR-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.
The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling.
The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.
The Up-Regulation of Histone Deacetylase 8 Promotes Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma.
Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex.
Upregulation of miR-362-3p modulates proliferation and anchorage-independent growth by directly targeting Tob2 in hepatocellular carcinoma.
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
[Inhibition of curcumin on histone deacetylase and expression promotion of P21 (WAF1/CIP1) in HepG2 cells]
[RNA interference of HDAC7 expression in hepatocellular carcinoma.]
Carcinoma, Intraductal, Noninfiltrating
Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies.
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.
Carcinoma, Mucoepidermoid
Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells.
Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas.
Carcinoma, Non-Small-Cell Lung
3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors.
A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors.
Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model.
Aurora A, aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Blocking NF-?B sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
cAMP signaling increases histone deacetylase 8 expression by inhibiting JNK-dependent degradation via autophagy and the proteasome system in H1299 lung cancer cells.
cAMP signaling increases histone deacetylase 8 expression via the Epac2-Rap1A-Akt pathway in H1299 lung cancer cells.
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells.
Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via histone deacetylase 7-mediated cytoskeleton regulation and angiogenic genes transcription.
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.
Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells.
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation.
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
Nuclear HDAC6 inhibits invasion by suppressing NF-?B/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.
Pax5 Re-Expression In H460 Cells Treated With The Combination Of Demethylating Agent And Histone Deacetylase Inhibitor Is Associated With The Enhancement Of P53 Binding To Pax5 Promoter Region.
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Up-regulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells.
Sodium Valproate Sensitizes Non-Small Lung Cancer A549 Cells to ?? T-Cell-Mediated Killing through Upregulating the Expression of MICA.
Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Stat3 inhibits Beclin 1 expression through recruitment of HDAC3 in nonsmall cell lung cancer cells.
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor.
Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
18?-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines.
Carcinoma, Renal Cell
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Combination Treatment of Renal Cell Carcinoma with Belinostat and 5-Fluorouracil: A Role for Oxidative Stress Induced DNA Damage and HSP90 Regulated Thymidine Synthase.
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
HDAC Inhibitors Synergize Antiproliferative Effect of Sorafenib in Renal Cell Carcinoma Cells.
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of ?-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.
Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
Histone Deacetylase Inhibitors Modulate Renal Cell Carcinoma Sensitivity to TRAIL/Apo-2L-induced Apoptosis by Enhancing TRAIL-R2 Expression.
Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID ALTERS GROWTH PROPERTIES OF RENAL CELL CARCINOMA IN VITRO AND IN VIVO.
The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
Carcinoma, Small Cell
Histone deacetylase inhibitors synergizes with catalytic inhibitors of EZH2 to exhibit anti-tumor activity in small cell carcinoma of the ovary, hypercalcemic type.
Carcinoma, Squamous Cell
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.
Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma.
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells.
Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Effects of trichostatin A on HIF-1? and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.
Functional variants of the NEIL1 and NEIL2 genes and risk and progression of squamous cell carcinoma of the oral cavity and oropharynx.
Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression.
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression.
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma.
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
Histone deacetylase inhibitors in oral squamous cell carcinoma treatment.
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
Positive and negative regulation of podoplanin expression by TGF-? and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines.
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Quantitative phosphoproteomic analysis reveals ?-bisabolene inducing p53-mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1/2 activation.
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.
Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3.
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
The histone deacetylase inhibitor, Trichostatin A, induces G2/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells.
Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma.
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
[Down-regulation of histone deacetylase 2 induces cell apoptosis and inhibits cell proliferation and migration of laryngeal squamous cell carcinoma cells].
[Effects of downregulation of HDAC6 expression on cell cycle, proliferation and migration of laryngeal squamous cell carcinoma].
Carcinoma, Transitional Cell
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.
Cardio-Renal Syndrome
Cardiac-Specific Overexpression of Silent Information Regulator 1 Protects Against Heart and Kidney Deterioration in Cardiorenal Syndrome via Inhibition of Endoplasmic Reticulum Stress.
Cardiomegaly
Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy.
CAMTA in cardiac hypertrophy.
Casein kinase-2?1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart.
CKIP-1 inhibits cardiac hypertrophy by regulating class II histone deacetylase phosphorylation through recruiting PP2A.
Class II HDACs mediate CaMK-dependent signaling to NRSF in ventricular myocytes.
Dichotomy of Ca in the heart: contraction versus intracellular signaling.
Effect of the angiotensin II receptor blocker valsartan on cardiac hypertrophy and myocardial histone deacetylase expression in rats with aortic constriction.
Effects of a novel histone deacetylase inhibitor, N-(2-aminophenyl) benzamide, on a reversible hypertrophy induced by isoproterenol in in situ rat hearts.
Estrogen regulates histone deacetylases to prevent cardiac hypertrophy.
HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy.
HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage.
HDAC Inhibition Suppresses Cardiac Hypertrophy and Fibrosis in DOCA-Salt Hypertensive Rats via Regulation of HDAC6/HDAC8 Enzyme Activity.
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.
HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy.
Histone Deacetylase Inhibition Attenuates Cardiac Hypertrophy and Fibrosis through Acetylation of Mineralocorticoid Receptor in Spontaneously Hypertensive Rats.
Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).
Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.
Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development.
Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy.
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure.
Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2.
Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy.
Integrated mechanisms of CaMKII-dependent ventricular remodeling.
Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy.
Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity.
Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice.
Nuclear calcium/calmodulin-dependent protein kinase IIdelta preferentially transmits signals to histone deacetylase 4 in cardiac cells.
Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation.
Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts.
Potential non-oncological applications of histone deacetylase inhibitors.
PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart.
Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5.
Regulation of Acetylation of Histone Deacetylase 2 by p300/CBP-Associated Factor/Histone Deacetylase 5 in the Development of Cardiac Hypertrophy.
Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.
Sodium Butyrate Controls Cardiac Hypertrophy in Experimental Models of Rats.
Suppression of HDAC Nuclear Export and Cardiomyocyte Hypertrophy by Novel Irreversible Inhibitors of CRM1.
The mechanism of myocardial hypertrophy regulated by the interaction between mhrt and myocardin.
The role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy.
Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy.
YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5.
Cardiomyopathies
Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy.
Diet-induced lethality due to loss of HDAC3 in heart and skeletal muscle.
HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving ?-tubulin acetylation.
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
Inflammation leads through PGE/EP3 signaling to HDAC5/MEF2-dependent transcription in cardiac myocytes.
The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism.
Cardiomyopathy, Dilated
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
Cardiotoxicity
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
Changes in cardiac NaV1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.
HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving ?-tubulin acetylation.
The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity.
Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.
Cardiovascular Diseases
Activation of PPAR alpha by fenofibrate inhibits apoptosis in vascular adventitial fibroblasts partly through SIRT1-mediated deacetylation of FoxO1.
Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
Cyclic phosphatidic acid inhibits alkyl-glycerophosphate-induced downregulation of histone deacetylase 2 expression and suppresses the inflammatory response in human coronary artery endothelial cells.
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Histone deacetylase 5 interacts with Krüppel-like factor 2 and inhibits its transcriptional activity in endothelium.
Histone deacetylase inhibitors: Keeping momentum for neuromuscular and cardiovascular diseases treatment.
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid.
Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors.
Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
SIRT3 attenuates AngII-induced cardiac fibrosis by inhibiting myofibroblasts transdifferentiation via STAT3-NFATc2 pathway.
Sirtuin 1 retards hyperphosphatemia-induced calcification of vascular smooth muscle cells.
Sirtuin 1 rs1467568 and rs7895833 in South African Indians with early-onset coronary artery disease.
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy.
Cataract
Effects of microRNA-211 on proliferation and apoptosis of lens epithelial cells by targeting SIRT1 gene in diabetic cataract mice.
Cell Transformation, Neoplastic
Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.
Central Nervous System Diseases
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
Cerebellar Ataxia
A SEPSECS mutation in a 23-year-old woman with microcephaly and progressive cerebellar ataxia.
Cerebral Hemorrhage
Histone Deacetylase Inhibitor Scriptaid Alleviated Neurological Dysfunction after Experimental Intracerebral Hemorrhage in Mice.
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Confers Acute Neuroprotection After Intracerebral Hemorrhage in Mice.
Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
Cerebrovascular Disorders
Correlation between Histone Deacetylase 9 and Regulatory T Cell in Patients with Chronic Heart Failure.
Charcot-Marie-Tooth Disease
Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.
Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease.
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
Cheilitis
Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.
Chickenpox
Histone Deacetylase 1 and 2 are Phosphorylated at Novel Sites During Varicella Zoster Virus Infection.
Cholangiocarcinoma
CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.
Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis.
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor Growth.
Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells.
MiR-433 and miR-22 dysregulations induce HDAC6 overexpression and ciliary loss in cholangiocarcinoma.
Peanut testa extracts possessing histone deacetylase inhibitory activity induce apoptosis in cholangiocarcinoma cells.
Role of histone deacetylase expression in intrahepatic cholangiocarcinoma.
SPRR2a enhances p53 deacetylation through HDAC1 and down regulates p21 promoter activity.
Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
TGF-?1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4.
Choledochal Cyst
Carcinogenic Potential of Biliary Epithelium of Congenital Choledochal Cyst Model in Rats: A Special Reference to HDAC Expression.
Cholestasis
Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1.
Cholestasis, Intrahepatic
Effect of Histone Deacetylase HDAC3 on Cytokines IL-18, IL-12 and TNF-? in Patients with Intrahepatic Cholestasis of Pregnancy.
Chondrocalcinosis
The new bone biology: pathologic, molecular, and clinical correlates.
Chondrosarcoma
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.
HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.
HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia.
Histone deacetylase inhibitors repress chondrosarcoma cell proliferation.
MicroRNA?10b suppresses the migration and invasion of chondrosarcoma cells by targeting brain?derived neurotrophic factor.
Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines.
The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells.
Chordoma
Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.
Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: An immunohistochemical and functional analysis.
Choriocarcinoma
A new approach combining LC-MS and multivariate statistical analysis for revealing changes in histone modification levels.
Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation.
Epigenetic therapy in human choriocarcinoma.
Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines.
Expression of histone deacetylases 1, 2 and 3 in histological subtypes of testicular germ cell tumours.
Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells.
Hypermethylation of SOX2 gene in hydatidiform mole and choriocarcinoma.
Choroidal Neovascularization
Attenuation of choroidal neovascularization by histone deacetylase inhibitor.
The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model.
Chronic Kidney Disease-Mineral and Bone Disorder
Klotho preservation via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice.
Chronic Periodontitis
Class I and II histone deacetylase expression in human chronic periodontitis gingival tissue.
Ciliopathies
Ciliopathies: Does HDAC6 Represent a New Therapeutic Target?
Cleidocranial Dysplasia
The new bone biology: pathologic, molecular, and clinical correlates.
Cockayne Syndrome
Cockayne Syndrome group B protein stimulates NEIL2 DNA glycosylase activity.
Colitis
A Highly Potent and Selective Histone Deacetylase 6 Inhibitor Prevents DSS-induced Colitis in Mice.
An HDAC6 Inhibitor Confers Protection and Selectively Inhibits B-Cell Infiltration in DSS-Induced Colitis in Mice.
CaM kinase II in colonic smooth muscle contributes to dysmotility in murine DSS-colitis.
Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Distinct Roles for Intestinal Epithelial Cell-Specific Hdac1 and Hdac2 in the Regulation of Murine Intestinal Homeostasis.
Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer.
Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1.
HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGF?1 signalling in inflammation.
HDAC6 and HSP90 Control The Functions Of Foxp3+ T-Regulatory Cells.
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid.
Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
SUMOylation of ROR-?t inhibits IL-17 expression and inflammation via HDAC2.
The acetylome regulators Hdac1 and Hdac2 differently modulate intestinal epithelial cell dependent homeostatic responses in experimental colitis.
The HDAC Inhibitor, SAHA, Prevents Colonic Inflammation by Suppressing Pro-inflammatory Cytokines and Chemokines in DSS-induced Colitis.
Colonic Neoplasms
3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin.
9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma.
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells.
A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells.
A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells.
Aceroside VIII is a New Natural Selective HDAC6 Inhibitor that Synergistically Enhances the Anticancer Activity of HDAC Inhibitor in HT29 Cells.
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.
Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells.
An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.
Anti-invasive effects and proapoptotic activity induction by the rexinoid IIF and valproic acid in combination on colon cancer cell lines.
Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients.
Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction.
Application of partial least squares discriminant analysis and variable selection procedures: a 2D-PAGE proteomic study.
Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells.
Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation.
Calcium-sensing receptor silencing in colorectal cancer is associated with promoter hypermethylation and loss of acetylation on histone 3.
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets.
CBP Activity Mediates Effects of the Histone Deacetylase Inhibitor Butyrate on WNT Activity and Apoptosis in Colon Cancer Cells.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo.
Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3.
Colonic health: fermentation and short chain fatty acids.
Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity.
Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis.
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors.
Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory.
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles.
Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.
Epigenetic regulation of the 1,25-dihydroxyvitamin D(3) 24-hydroxylase (CYP24A1) in colon cancer cells.
Epigenetic silencing of the sulfate transporter gene DTDST induces sialyl Lewisx expression and accelerates proliferation of colon cancer cells.
Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer.
Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer.
G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer.
Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells.
HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha.
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity.
HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.
HDAC3 overexpression and colon cancer cell proliferation and differentiation.
HDAC4 promotes growth of colon cancer cells via repression of p21.
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells.
Heterocyclic Analogs of Sulforaphane Trigger DNA Damage and Impede DNA Repair in Colon Cancer Cells: Interplay of HATs and HDACs.
Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer.
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells.
Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells.
Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of CDKN1A.
Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.
Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly.
Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase.
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Inhibition of growth and induction of differentiation markers by polyphenolic molecules and histone deacetylase inhibitors in colon cancer cells.
Making sense of HDAC2 mutations in colon cancer.
Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins.
MicroRNA-429 inhibits the migration and invasion of colon cancer cells by targeting PAK6/cofilin signaling.
MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.
Nardilysin controls intestinal tumorigenesis through HDAC1/p53-dependent transcriptional regulation.
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators.
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.
Quantitative Analysis of Histone Deacetylase-1 Selective Histone Modifications by Differential Mass Spectrometry.
Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection.
SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin.
Selenium-binding protein 1 is associated with the degree of colorectal cancer differentiation and is regulated by histone modification.
Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line.
Sp1 is a transcription repressor to stanniocalcin-1 expression in TSA-treated human colon cancer cells, HT29.
Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis.
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Sulfide-detoxifying enzymes in the human colon are decreased in cancer and upregulated in differentiation.
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice.
Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.
Sumoylation of HDAC2 promotes NF-?B-dependent gene expression.
Synthesis and biological activity of diisothiocyanate-derived mercapturic acids.
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.
The Australian fruit Illawarra plum (Podocarpus elatus Endl., Podocarpaceae) inhibits telomerase, increases histone deacetylase activity and decreases proliferation of colon cancer cells.
The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling.
The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells.
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
The Intestinal Epithelial Cell Differentiation Marker Intestinal Alkaline Phosphatase (ALPi) Is Selectively Induced by Histone Deacetylase Inhibitors (HDACi) in Colon Cancer Cells in a Kruppel-like Factor 5 (KLF5)-dependent Manner.
The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.
The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production.
The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer.
Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway?
Trichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells.
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
[Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines]
Colorectal Neoplasms
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer.
A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKC? and E-cadherin.
A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Anti-Tumor Effects of Paeoniflorin on Epithelial-To-Mesenchymal Transition in Human Colorectal Cancer Cells.
Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo.
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
Butyrate production from high-fiber diet protects against lymphoma tumor.
Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner.
Carcinoembryonic Antigen Expression and Resistance to Radiation and 5-Fluorouracil-Induced Apoptosis and Autophagy.
CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma.
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo.
Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity.
Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy.
Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Deregulated expression of HDAC3 in colorectal cancer and its clinical significance.
Determination of the Role of CBP- and p300-Mediated Wnt Signaling on Colonic Cells.
Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
Efficacy of butyrate analogues in HT-29 cancer cells.
Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells.
Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer.
ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells.
Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer.
Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.
Evaluation of NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and SMUG1 genes in familial colorectal cancer predisposition.
Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma.
Expression of HDAC1 and CBP/p300 in human colorectal carcinomas.
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
HDAC1 controls CIP2A transcription in human colorectal cancer cells.
HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers.
HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression.
Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.
Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail.
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells.
Histone deacetylase inhibitors and colorectal cancer: what is new?
Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects.
Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization.
In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
Increased transforming growth factor ? and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients.
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state.
Ku70 is essential for histone deacetylase inhibitor trichostatin A-induced apoptosis.
Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation.
MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer.
MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer.
MiR-761 inhibits colorectal cancer cell proliferation and invasion through targeting HDAC1.
MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
Mutational analysis of mononucleotide repeats in HDAC4, 5, 6, 7, 9 and 11 genes in gastric and colorectal carcinomas with microsatellite instability.
Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1.
Novel ?-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer.
OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Potential Anticancer Properties and Mechanisms of Action of Curcumin.
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs.
Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells.
Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.
Regulation of prostaglandin transporters in colorectal neoplasia.
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf.
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter.
Structure-activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT-116 human colorectal cancer cells.
Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells.
Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers.
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.
Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
TCF7L1 recruits CtBP and HDAC1 to repress DICKKOPF4 gene expression in human colorectal cancer cells.
The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes.
The contribution of activating transcription factor 3 to apoptosis of human colorectal cancer cells by protocatechualdehyde, a naturally occurring phenolic compound.
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.
The HDAC6 inhibitor ACY?1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
The HDAC6 Inhibitor Tubacin Induces Release of CD133(+) Extracellular Vesicles From Cancer Cells.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways.
The microbiome and its potential as a cancer preventive intervention.
The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment.
The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.
Transforming pathways unleashed by a HDAC2 mutation in human cancer.
Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis.
Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.
Untangling the fiber yarn: butyrate feeds Warburg to suppress colorectal cancer.
Up-regulation of UVRAG by HDAC1 Inhibition Attenuates 5FU-induced Cell Death in HCT116 Colorectal Cancer Cells.
Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer.
Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC.
[Validation and Evaluation of Diagnostic Efficiency of Genes Associated with Colorectal Cancer with Hyperglycemia].
Colorectal Neoplasms, Hereditary Nonpolyposis
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Communicable Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
HDAC inhibitors in parasitic diseases.
Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies.
Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease.
Congenital Abnormalities
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.
OCT4A contributes to the stemness and multi-potency of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs).
Corneal Neovascularization
Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model.
Coronary Artery Disease
Deficiency of the stroke relevant HDAC9 gene attenuates atherosclerosis in accord with allele-specific effects at 7p21.1.
Polymorphism of HDAC9 Gene Is Associated with Increased Risk of Acute Coronary Syndrome in Chinese Han Population.
Craniocerebral Trauma
[INVOLVEMENT OF EPIGENETIC REGULATION IN CEREBRAL CELL DEATH FOLLOWING TRAUMATIC BRAIN INJURY IN A RAT MODEL].
Craniofacial Abnormalities
Murine craniofacial development requires Hdac3-mediated repression of Msx gene expression.
Craniosynostoses
The new bone biology: pathologic, molecular, and clinical correlates.
Cryptorchidism
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
Cushing Syndrome
Histone Deacetylase Inhibition Ameliorates Hypertension and Hyperglycemia in a model of Cushing's Syndrome.
Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing's syndrome.
Cystic Fibrosis
Clinical and experimental applications of sodium phenylbutyrate.
CTCF regulates positioning of the human cystic fibrosis gene in association with a histone deacetylase.
HDAC7: a viable target in the treatment of cystic fibrosis.
High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph+ leukemia through the HDAC2-mediated PTEN pathway.
Histone acetylation and deacetylation: importance in inflammatory lung diseases.
Improved Growth Patterns in Cystic Fibrosis Mice after Loss of Histone Deacetylase 6.
Perinuclear positioning of the inactive human cystic fibrosis gene depends on CTCF, A-type lamins and an active histone deacetylase.
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
Regulation of the Coxsackie and adenovirus receptor expression is dependent on cystic fibrosis transmembrane regulator in airway epithelial cells.
Rescuing Trafficking Mutants of the ATP-binding Cassette Protein, ABCA4, with Small Molecule Correctors as a Treatment for Stargardt Eye Disease.
Small-Molecule Screening for Genetic Diseases.
The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation.
Cystitis
Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis.
Cysts
Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds.
AN INHIBITOR OF HISTONE DEACETYLASE 6 ACTIVITY, ACY-1215, REDUCES cAMP and CYST GROWTH IN POLYCYSTIC KIDNEY DISEASE.
CCAAT/Enhancer-Binding Protein ? Is Epigenetically Silenced by Histone Deacetylation in Endometriosis and Promotes the Pathogenesis of Endometriosis.
Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models.
Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Deletion of ADP Ribosylation Factor-Like GTPase 13B Leads to Kidney Cysts.
HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
Histone deacetylase 6 Inhibition reduces cysts by decreasing via cAMP and Ca2+ in knockout mouse models of polycystic kidney disease.
Histone deacetylases 6 increases the cyclic adenosine monophosphate level and promotes renal cyst growth.
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts.
The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42.
Therapeutic Targets In Polycystic Liver Disease.
De Lange Syndrome
A commentary on exome sequencing identifies a de novo mutation in HDAC8 associated with Cornelia de Lange syndrome.
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
A Functional Mutation in HDAC8 Gene as Novel Diagnostic Marker for Cornelia De Lange Syndrome.
Biochemical and structural characterization of HDAC8 mutants associated with Cornelia de Lange syndrome spectrum disorders.
Compromised structure and function of HDAC8 mutants identified in Cornelia de Lange Syndrome spectrum disorders.
Cornelia de Lange syndrome in diverse populations.
Exome sequencing identifies a de novo mutation in HDAC8 associated with Cornelia de Lange syndrome.
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle.
Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation.
Molecular characterization of HDAC8 deletions in individuals with atypical Cornelia de Lange syndrome.
Molecular characterization of two novel intronic variants of NIPBL gene detected in unrelated Cornelia de Lange syndrome patients.
Mutant cohesin affects RNA polymerase II regulation in Cornelia de Lange syndrome.
NIPBL Controls RNA Biogenesis to Prevent Activation of the Stress Kinase PKR.
Rare copy number variants contribute pathogenic alleles in patients with intestinal malrotation.
Structural aspects of HDAC8 mechanism and dysfunction in Cornelia de Lange syndrome spectrum disorders.
[NIPBL gene mutations in two children with Cornelia de Lange syndrome].
Deafness
A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness.
Dementia
Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions.
Arsenic toxicity induced endothelial dysfunction and dementia: Pharmacological interdiction by histone deacetylase and inducible nitric oxide synthase inhibitors.
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Post-occlusion administration of sodium butyrate attenuates cognitive impairment in a rat model of chronic cerebral hypoperfusion.
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
Turning back the clock on neurodegeneration.
Demyelinating Diseases
Epigenetic in Multiple Sclerosis: Molecular mechanisms and dietary intervention.
HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage.
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Dermatitis
The histone deacetylase inhibitor, trichostatin A, inhibits the development of 2,4-dinitrofluorobenzene-induced dermatitis in NC/Nga mice.
Dermatitis, Contact
Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors.
Diabetes Complications
Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy.
Diabetes Mellitus
Acute exercise and periodized training in different environments affect histone deacetylase activity and interleukin-10 levels in peripheral blood of patients with type 2 diabetes.
Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus.
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention.
Diabetes Mellitus, Type 1
Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes.
Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.
Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes.
Novel methods of type 1 diabetes treatment.
Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.
Use of a cocktail regimen consisting of soluble galectin-1, rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes.
Diabetes Mellitus, Type 2
Acute exercise and periodized training in different environments affect histone deacetylase activity and interleukin-10 levels in peripheral blood of patients with type 2 diabetes.
HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells.
Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats.
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes.
Histone deacetylase regulates insulin signaling via two pathways in pancreatic ? cells.
Histone modifications and skeletal muscle metabolic gene expression.
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue.
MC1568 improves insulin secretion in islets from type 2 diabetes patients and rescues ?-cell dysfunction caused by Hdac7 upregulation.
Sirtuin1 (Sirt1) Promotes Cortical Bone Formation by Preventing ?-Catenin Sequestration by FoxO Transcription Factors in Osteoblast Progenitors.
Trichostatin A affects the secretion pathways of beta and intestinal endocrine cells.
Diabetic Cardiomyopathies
Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
Diabetic Nephropathies
Glomerular mesangial cell and podocyte injuries in diabetic nephropathy.
HDAC4 blocks autophagy to trigger podocyte injury: non-epigenetic action in diabetic nephropathy.
Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy.
Histone Deacetylase Inhibitors and Diabetic Kidney Disease.
Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.
Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
Diabetic Retinopathy
Epigenetic control of early neurodegenerative events in diabetic retinopathy by the histone deacetylase SIRT6.
Diphtheria
Clinical Trials and Treatment of ATL.
[Adult T cell leukemia-lymphoma (ATL)].
Double Outlet Right Ventricle
Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-?1 (TGF-?1) to Orchestrate Second Heart Field Development.
Down Syndrome
Confirmed rare copy number variants implicate novel genes in schizophrenia.
Dyskinesias
RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study.
Dyslipidemias
MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex.
Polyphenols: Novel Signaling Pathways.
Encephalitis, Japanese
Histone deacetylase inhibition by Japanese encephalitis virus in monocyte/macrophages: a novel viral immune evasion strategy.
Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis.
Encephalomyelitis
A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis.
Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats.
The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord.
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis.
Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats.
Epigenetics of Multiple Sclerosis: An Updated Review.
The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord.
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Endocrine Gland Neoplasms
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Endocrine System Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Endometrial Neoplasms
A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation.
A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.